Heptares snags milestone from Cubist; SARS model could shed light on future spread of MERS coronavirus

 @FierceBiotech: Popular this weekend - Report: Pfizer backs off Onyx bid as price gets too rich. Article | Follow @FierceBiotech

 @JohnCFierce:  Report: Big Pharma mounts secret attack against data transparency rule - (some companies will never learn). Report | Follow @JohnCFierce

 @RyanMFierce: Roche is still undecided about new chair. Art Levinson dismissed as "too radical." Reutersarticle | Follow @RyanMFierce

 @EmilyMFierce: New 3-D model of diabetes target could shape drug design. More | Follow @EmilyMFierce

> Heptares Therapeutics says it has achieved its first milestone from a collaboration with Cubist ($CBST). Release

> Astex Pharmaceuticals says it has gathered data demonstrating "that early treatment with AT13387…in combination with targeted therapy delays the emergence of resistance. Release

Medical Device News

 @FierceMedDev: Med tech VC investing remains sluggish, biotech surges. Report | Follow @FierceMedDev

 @MarkHFierce: Google is backing Dx company SynapDx in its new $15.4M funding round. Release (PDF) | Follow @MarkHFierce

 @DamianFierce: Mela's melanoma-finding device was hailed as a major advance on FDA approval, but docs remain wary. Story | Follow @DamianFierce

> Saladax draws another $8M from GE to market cancer tests. News

> Medtronic's auto-adjust insulin pump on cusp of FDA approval. More

> ResMed wages patent battle with Chinese medical device maker. Item

Pharma News

 @FiercePharma: Chinese police pick up AstraZeneca sales rep for questioning. AZN says no reason to think it's part of bribery probe. Report | Follow @FiercePharma

 @CarlyHFierce: Reuters says Roche may have to turn to an outsider for its chairman hunt. News | Follow @CarlyHFierce

> Chile's CFR wins shareholder OK for Adcock buyout financing. Story

> GlaxoSmithKline exec admits 'breaches,' promises price cuts in China. Article

CRO News

> ResearchDx expands to meet contract diagnostics demand. Report

> CROs large and small get serious about eClinical. More

> Aesica teams with QRxPharma for abuse-deterrence tech. Item

> CRO Solutions spins niche services into new biz. Story

> AstraZeneca picks Tufts for outsourcing-heavy neuro program. Article

> WuXi, PRA snag ex-Theorem CEO to head China JV. News

Biotech IT News

> J&J searching for European digital health entrepreneurs. Item

> Chinese CRO buys software to bridge gap to global clients. More

> Bioinformatics buy bolsters Life Technologies' diagnostics pact with Merck Serono. Story

> With pharma clientele, Big Data-mapping startup Ayasdi lands $30.6M financing. Article

And Finally… Researchers say that the SARS epidemic provided a valuable model for how MERS is likely to spread in the wake of two upcoming pilgrimages in the Middle East. Release

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

The result, which beats the 35% reported by KRAS rival Amgen, sets Mirati up to file for FDA approval of the drug in the second half of next year.

Scorpion is working on precision oncology 2.0, including making better drugs for known targets, hitting undruggable targets and discovering new ones.